Clinical Trials on Waldenstrom's Macroglobulinemia Recurrent

Total 6548 results

Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

Recurrent Human Papillomavirus Type 16 Associated Cancer

United States
Immatics Biotechnologies GmbH
Bristol-Myers Squibb

Recruiting

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
Emory University

Terminated

Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

Recurrent Solid Tumors | High Risk Solid Tumors

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

HER2-positive Recurrent or Metastatic Malignant Solid Tumor

China
Brown Fertility

Withdrawn

Trial of Endometrial Scratch Prior to Frozen Embryo Transfer in Patients With Recurrent Implantation Failure

Recurrent Implantation Failure in Setting of Artifically Prepared Endometrium
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Immatics Biotechnologies GmbH

Recruiting

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
UNICANCER
Bristol-Myers Squibb

Completed

Nivolumab in Recurrent and/or Metastatic SCCHN (TopNIVO)

Recurrent and/or Metastatic Platinum-refractory SCCHN

France
Menoufia University

Completed

Evaluation of Conjunctival Autografting With MMC Application Versus Ologen Implantation of Recurrent Pterygium

Recurrent Pterygium of Eye
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Nanjing University

Completed

A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy (immunotherapy)

Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

China
National Cancer Institute (NCI)

Terminated

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
French Study Group on Chronic Lymphoid Leukemia
French Innovative Leukemia Organisation; Lymphoma Study Association; Département...

Completed

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Lymphoplasmacytic Lymphoma

France
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
Jorge J. Castillo, MD
Bristol-Myers Squibb

Terminated

Dasatinib In Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia | DASATINIB

United States
The First Affiliated Hospital of Soochow University

Unknown

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Treatment

China
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Lymphoma

United States
LifeTime Pharmaceuticals

Unknown

Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
NCIC Clinical Trials Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

Canada, United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Australia, United Kingdom, Canada, France
University of Nottingham

Unknown

Strategies for Management of Recurrent Pterygium (REPEAT)

Recurrent Pterygium
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Sunnybrook Health Sciences Centre
AstraZeneca

Recruiting

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)

Waldenstrom Macroglobulinemia

Canada
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Federico II University

Completed

Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients (OCTA)

Waldenstrom Macroglobulinemia

Italy
Janssen Pharmaceutical K.K.

Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

Japan
French Innovative Leukemia Organisation

Completed

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia (RemodelWM3)

Waldenstrom Macroglobulinemia

France
Hackensack Meridian Health
Onyx Therapeutics, Inc.

Completed

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Waldenstrom Macroglobulinemia

United States
Gilead Sciences

Terminated

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Polish Myeloma Consortium
Roche Pharma AG; Bioscience, S.A.

Unknown

A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 (OBI-1)

Waldenstrom Macroglobulinemia

Poland
Weill Medical College of Cornell University
Celgene Corporation

Terminated

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (THRiL for WM)

Waldenstrom Macroglobulinemia

United States
University Hospital, Lille
Celgene Corporation

Completed

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia (RV-WM-0426)

Waldenstrom Macroglobulinemia

France
Ain Shams University
Capital Birth Center

Completed

Azathioprine in Recurrent Implantation Failure

In Vitro Fertilization | Recurrent Implantation Failure | Intracytoplsmic Sperm Injection

Egypt
Novartis Pharmaceuticals

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Japan
Meir Medical Center
Rambam Health Care Campus; Hadassah Medical Organization; Assaf-Harofeh Medical... and other collaborators

Unknown

Medial Retinacular Plication Versus Medial Patellofemoral Ligament Reconstruction for Recurrent Patellar Instability

Patella, Familial Recurrent Dislocation Of

Israel
UMC Utrecht

Completed

Maternal Embryo Interaction in Recurrent Miscarriages (MEER)

Recurrent Miscarriages

Netherlands
Fudan University

Unknown

Use of Cyclosporin A for the Treatment of Recurrent Miscarriage

Miscarriage, Recurrent

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
BeiGene

Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States, Puerto Rico
Shayna Sarosiek, MD
ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine in WM

Waldenstrom Macroglobulinemia

United States
Fundación Española de Hematología y Hemoterapía

Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies (PRAME)

Waldenstrom Macroglobulinemia

Spain
University College, London
Janssen-Cilag Ltd.

Recruiting

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)

Waldenstrom Macroglobulinemia

United Kingdom
Christian Buske
Hoffmann-La Roche; Johnson & Johnson; ClinAssess GmbH; University of Ulm; Zentrum...

Active, not recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia

Germany, Greece
Janssen Research & Development, LLC

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

China
University College, London
Merck Sharp & Dohme LLC

Completed

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM)

Waldenstrom Macroglobulinemia

United Kingdom
Dana-Farber Cancer Institute
AbbVie

Completed

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States

Clinical Trials on Waldenstrom's Macroglobulinemia Recurrent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations